Results 241 to 250 of about 28,869 (265)

Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B: week 144 results from a real‐world, multi‐centre cohort study

Alimentary Pharmacology and Therapeutics, 2022
Eiichi Ogawa, Norihiro Furusyo, Rie Sugimoto   +2 more
exaly  

Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group

International Journal of STD and AIDS, 2021
Jan Stępnicki, Tomasz Mikula, Alicja Wiercińska-Drapało   +2 more
exaly  

Bictegravir/emtricitabine/tenofovir-alafenamide

Reactions Weekly, 2023
  +4 more sources

Doxorubicin/tenofovir-alafenamide

Reactions Weekly, 2022
openaire   +1 more source

Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide

Journal of Antimicrobial Chemotherapy, 2019
Maddalena Cerrone, Megan Neary, Mark A Marzinke   +2 more
exaly  

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Lancet, The, 2017
Paul E Sax, Anton L Pozniak, María L Montes   +2 more
exaly  

Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence

Therapeutic Advances in Gastroenterology, 2018
Ivana Carey, Kosh Agarwal
exaly  

Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis.

Journal of Antimicrobial Chemotherapy
I. Chivite, L. Berrocal, E. de Lazzari, Soodabeh Navadeh, Carla Lluis-Ganella, A. Inciarte, Lorena de la Mora, A. González-Cordón, M. Martínez-Rebollar, M. Laguno, B. Torres, J. L. Blanco, Esteban Martínez, Josep Mallolas, J. Ambrosioni   +14 more
semanticscholar   +1 more source

Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate

Journal of Gastroenterology and Hepatology (Australia), 2019
Shun Kaneko, Masayuki Kurosaki, Nobuharu Tamaki   +2 more
exaly  

Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection

Expert Review of Clinical Pharmacology, 2017
John D Ryan, Robert G Gish
exaly